American Journal of Cardiology
Volume 104, Issue 1 , Pages 29-35 , 1 July 2009

Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein Cholesterol Levels With Rosuvastatin 40 mg Daily (from the ASTEROID Study)

  • Stephen D. Wiviott, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0145; fax: 617-734-7329
    • ,
  • Satishkumar Mohanavelu, MS

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Joel S. Raichlen, MD

      Affiliations

    • AstraZeneca, Wilmington, Delaware
    • ,
  • Valerie A. Cain, MS

      Affiliations

    • AstraZeneca, Wilmington, Delaware
    • ,
  • Steven E. Nissen, MD

      Affiliations

    • Cardiovascular Division, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Peter Libby, MD

      Affiliations

    • Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Received 2 October 2008 ,Revised 20 February 2009 ,Accepted 20 February 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The ASTEROID Study was sponsored by AstraZeneca, Wilmington, Delaware. Dr. Wiviott has received honoraria for speaking at Continuing Medical Education programs and consultant fees from AstraZeneca (Wilmington, Delaware), Pfizer (New York, New York), and Merck-Schering Plough (Whitehouse Station, New Jersey). Dr. Raichlen and Ms. Cain are employees of AstraZeneca (Wilmington, Delaware). Dr. Nissen has received research support from AstraZeneca (Wilmington, Delaware), Eli Lilly (Indianapolis, Indiana), Pfizer (New York, New York), Takeda (Osaka, Japan), Daiichi Sankyo (Parsippany, New Jersey), and Sanofi-Aventis (Bridgewater, New Jersey). Dr. Nissen has consulted for a number of pharmaceutical companies without financial compensation. All honoraria, consulting fees, or other payments from any for-profit entity are paid directly to charity, so that neither income nor any tax deduction is received. Dr. Libby does not accept payments from pharmaceutical companies; he serves as an unpaid consultant, speaker, and clinical trial participant for AstraZeneca (Wilmington, Delaware), Merck (Whitehouse Station, New Jersey), Pfizer (New York, New York), and Schering Plough (Kenilworth, New Jersey).

PII: S0002-9149(09)00659-6

doi: 10.1016/j.amjcard.2009.02.040

American Journal of Cardiology
Volume 104, Issue 1 , Pages 29-35 , 1 July 2009

Article Tools

* Image Usage & Resolution